Prior to Amylin, Ms Graham served as group chairman, office of the president, for Guidant, a cardiovascular medical device manufacturer, and held a number of management positions at Eli Lilly and Company.
Ms Graham has received a bachelor of science in agricultural economics from the University of Arkansas. Ms Graham also holds an MBA from Harvard University.
Randy Scott, chairman and CEO of Genomic Health, said: “Ginger brings a wealth of industry leadership experience to Genomic Health’s board of directors, with expertise in developing and commercializing successful products for pharmaceutical and medical device companies.
“Her appointment comes at an opportune time as we continue to expand our commercial efforts outside of the US and invest in our product pipeline, as part of our mission to make individualized treatment standard practice for all cancer patients.”